+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Enhancer Of Zeste Homolog 2 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Enhancer Of Zeste Homolog 2 Protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cushing Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Cushing Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Type 2 Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Chronic Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Gout - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
22q11.2 Deletion Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

22q11.2 Deletion Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Acute Hepatic Porphyria (AHP) - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Hepatic Porphyria (AHP) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Growth Hormone Deficiency (GHD) - Pipeline Insight, 2025 - Product Thumbnail Image

Growth Hormone Deficiency (GHD) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Chronic Refractory Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Refractory Gout - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Proliferative Diabetic Retinopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Proliferative Diabetic Retinopathy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Hypoglycemia - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Hypoglycemia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Gigantism - Pipeline Insight, 2025 - Product Thumbnail Image

Gigantism - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Cardiac Amyloidosis- Pipeline Insight, 2025 - Product Thumbnail Image

Cardiac Amyloidosis- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Zollinger Ellison Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Zollinger Ellison Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Neuropathy- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Neuropathy- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
From
Acute Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Lactose Intolerance - Pipeline Insight, 2025 - Product Thumbnail Image

Lactose Intolerance - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Proteus Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Proteus Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adrenal Insufficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Adrenal Insufficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more